214 related articles for article (PubMed ID: 10565769)
1. Reproducibility of metabolic measurements in malignant tumors using FDG PET.
Weber WA; Ziegler SI; Thödtmann R; Hanauske AR; Schwaiger M
J Nucl Med; 1999 Nov; 40(11):1771-7. PubMed ID: 10565769
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors.
Nahmias C; Wahl LM
J Nucl Med; 2008 Nov; 49(11):1804-8. PubMed ID: 18927325
[TBL] [Abstract][Full Text] [Related]
3. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
4. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
6. Carbon-11-thymidine and FDG to measure therapy response.
Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
[TBL] [Abstract][Full Text] [Related]
8. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet N; Albert A; Foidart J; Hustinx R
J Nucl Med; 2004 May; 45(5):784-8. PubMed ID: 15136627
[TBL] [Abstract][Full Text] [Related]
9. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of tumor metabolism using FDG-PET imaging.
Weber WA; Schwaiger M; Avril N
Nucl Med Biol; 2000 Oct; 27(7):683-7. PubMed ID: 11091112
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
Fukunaga T; Okazumi S; Koide Y; Isono K; Imazeki K
J Nucl Med; 1998 Jun; 39(6):1002-7. PubMed ID: 9627333
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Cook GJ; Houston S; Barrington SF; Fogelman I
J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
[TBL] [Abstract][Full Text] [Related]
13. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
[TBL] [Abstract][Full Text] [Related]
14. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
15. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.
de Langen AJ; Vincent A; Velasquez LM; van Tinteren H; Boellaard R; Shankar LK; Boers M; Smit EF; Stroobants S; Weber WA; Hoekstra OS
J Nucl Med; 2012 May; 53(5):701-8. PubMed ID: 22496583
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
17. Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
Avril N; Bense S; Ziegler SI; Dose J; Weber W; Laubenbacher C; Römer W; Jänicke F; Schwaiger M
J Nucl Med; 1997 Aug; 38(8):1186-91. PubMed ID: 9255146
[TBL] [Abstract][Full Text] [Related]
18. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
Minn H; Zasadny KR; Quint LE; Wahl RL
Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional clinical PET in lung cancer: validation and practical strategies.
Calvo R; Martí-Climent JM; Richter JA; Peñuelas I; Crespo-Jara A; Villar LM; García-Velloso MJ
J Nucl Med; 2000 Mar; 41(3):439-48. PubMed ID: 10716316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
